Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MHLW Approves Erbitax, Thymoglobulin And Mycobutin

This article was originally published in PharmAsia News

Executive Summary

The Second Division of the Pharmaceutical and Food Sanitation Council of the Ministry of Health, Labor and Welfare approved three drugs May 23: Merck's Erbitax (cetuximab), Sanofi-Aventis' Thymoglobulin IV infusion and Pfizer's Mycobutin (rifabutin). Cetuximab is the second approved molecular-targeted colon and rectum cancer drug after Chugai's Avastin (bevacizumab). Thymoglobulin is applied to treat moderate to severe aplastic anemia. Mycobutin is used to treat tuberculosis and prevent disseminated mycobacterium avium complex, a disease in patients with advanced HIV infection. After the division reports the items to the Pharmaceutical Affairs section meeting in June, formal approvals are estimated to be in middle July. (Click here for more - Japanese language

Table

View full table

Tags:
Latest Headlines

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

See All
UsernamePublicRestriction

Register

SC068603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By